Chawki Sylvain, Ploussard Guillaume, Montlahuc Claire, Verine Jérome, Mongiat-Artus Pierre, Desgrandchamps François, Molina Jean-Michel
Department of Infectious Diseases, Saint Louis Hospital, Assistance Publique Hôpitaux de Paris, Université de Paris Diderot, Paris 7, Sorbonne Paris Cité, Paris, France.
Department of Urology, Saint Louis Hospital, Assistance Publique Hôpitaux de Paris, Université de Paris Diderot, Paris 7, Sorbonne Paris Cité, Paris, France.
PLoS One. 2015 Dec 7;10(12):e0144237. doi: 10.1371/journal.pone.0144237. eCollection 2015.
Non-AIDS-related malignancies now represent a frequent cause of death among HIV-infected patients. Albeit bladder cancer is one of the most common malignancies worldwide, it has been rarely reported among HIV-infected patients. We wished to assess the prevalence and characteristics of bladder cancer in HIV-infected patients.
We conducted a single center retrospective study from 1998 to 2013 in a university hospital in Paris. Cases of bladder cancer among HIV-infected patients were identified using the electronic records of the hospital database and of the HIV-infected cohort. Patient characteristics and outcomes were retrieved from patients charts. A systematic review of published cases of bladder cancers in patients with HIV-infection was also performed.
During the study period we identified 15 HIV-infected patients (0.2% of the cohort) with a bladder cancer. Patients were mostly men (73%) and smokers (67%), with a median age of 56 years at cancer diagnosis. Bladder cancer was diagnosed a median of 14 years after HIV-infection. Most patients were on ART (86%) with median current and nadir CD4 cell counts of 506 and 195 cells/mm3, respectively. Haematuria (73%) was the most frequent presenting symptom and HPV-associated lesions were seen in 6/10 (60%) patients. Histopathology showed transitional cell carcinoma in 80% and a high proportion of tumors with muscle invasion (47%) and high histologic grade (73%). One-year survival rate was 74.6%. The systematic review identified 13 additional cases of urothelial bladder cancers which shared similar features.
Bladder cancers in HIV-infected patients remain rare but may occur in relatively young patients with a low nadir CD4 cell count, have aggressive pathological features and can be fatal.
非艾滋病相关恶性肿瘤现已成为HIV感染患者常见的死亡原因。尽管膀胱癌是全球最常见的恶性肿瘤之一,但在HIV感染患者中却鲜有报道。我们希望评估HIV感染患者中膀胱癌的患病率及特征。
我们于1998年至2013年在巴黎一家大学医院开展了一项单中心回顾性研究。利用医院数据库和HIV感染队列的电子记录识别HIV感染患者中的膀胱癌病例。从患者病历中获取患者特征及预后情况。我们还对已发表的HIV感染患者膀胱癌病例进行了系统综述。
在研究期间,我们识别出15例HIV感染的膀胱癌患者(占队列的0.2%)。患者多为男性(73%)且有吸烟史(67%),癌症诊断时的中位年龄为56岁。膀胱癌在HIV感染后中位14年被诊断出来。大多数患者正在接受抗逆转录病毒治疗(86%),当前及最低CD4细胞计数的中位数分别为506和195个细胞/mm³。血尿(73%)是最常见的症状,6/10(60%)的患者可见与人乳头瘤病毒相关的病变。组织病理学显示80%为移行细胞癌,且有高比例的肿瘤侵犯肌肉(47%)和高组织学分级(73%)。一年生存率为74.6%。系统综述又发现了13例具有相似特征的尿路上皮膀胱癌病例。
HIV感染患者中的膀胱癌仍然罕见,但可能发生在相对年轻、最低CD4细胞计数较低的患者中,具有侵袭性病理特征且可能致命。